TR200401772T4 - hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri. - Google Patents

hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri.

Info

Publication number
TR200401772T4
TR200401772T4 TR2004/01772T TR200401772T TR200401772T4 TR 200401772 T4 TR200401772 T4 TR 200401772T4 TR 2004/01772 T TR2004/01772 T TR 2004/01772T TR 200401772 T TR200401772 T TR 200401772T TR 200401772 T4 TR200401772 T4 TR 200401772T4
Authority
TR
Turkey
Prior art keywords
thiazole derivatives
substituted oxazole
hppar alpha
alpha activators
straight
Prior art date
Application number
TR2004/01772T
Other languages
English (en)
Inventor
Michael Sierra Lawrence
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9928561.1A external-priority patent/GB9928561D0/en
Priority claimed from GB0003500A external-priority patent/GB0003500D0/en
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200401772T4 publication Critical patent/TR200401772T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formül (I)'e ait bir bilesik ve bunun farmasötik açidan kabul gören tuzlari, solvatlari ve hidrolize edilebilir esterleri: ki buradaki: X1, O veya S'dir; R1 ve R2, bagimsiz bir sekilde, H, halojen, -CH3 ve -OCH3'tür; n, 1 veya 2'dir; X2, NH, NCH3 veya O'dur; Y ve Z'den biri N'dir, digeri de O veya S'dir; R3, fenil veya piridildir (ki buradaki N, 2 veya 3 pozisyonundadir) ve R3'ün piridil olmasi durumunda N'nin ikame edilmemis olmasi sartiyla bir veya daha fazla halojen, NO2, NH2, CF3, OCF3, OC1-6 düz veya dalli alkil, C1-6 düz veya dalli alkil, alkenil veya alkinil ile istege göre ikame edilir; R4, CF3 veya CH3'tür.
TR2004/01772T 1999-12-02 2000-11-30 hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri. TR200401772T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928561.1A GB9928561D0 (en) 1999-12-02 1999-12-02 Chemical compounds
GB0003500A GB0003500D0 (en) 2000-02-15 2000-02-15 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200401772T4 true TR200401772T4 (tr) 2004-09-21

Family

ID=26243654

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/01772T TR200401772T4 (tr) 1999-12-02 2000-11-30 hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri.
TR2002/01473T TR200201473T2 (tr) 1999-12-02 2000-11-30 Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/01473T TR200201473T2 (tr) 1999-12-02 2000-11-30 Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri

Country Status (27)

Country Link
US (1) US6518290B1 (tr)
EP (1) EP1244642B1 (tr)
JP (1) JP3884290B2 (tr)
KR (1) KR100706735B1 (tr)
CN (1) CN1184215C (tr)
AR (1) AR035631A1 (tr)
AT (1) ATE265442T1 (tr)
AU (1) AU758758B2 (tr)
BR (1) BR0016067A (tr)
CA (1) CA2393190A1 (tr)
CO (1) CO5251452A1 (tr)
CZ (1) CZ20021903A3 (tr)
DE (1) DE60010333T2 (tr)
DK (1) DK1244642T3 (tr)
ES (1) ES2219423T3 (tr)
GC (1) GC0000215A (tr)
HK (1) HK1047435B (tr)
HU (1) HUP0203532A3 (tr)
IL (2) IL149582A0 (tr)
MX (1) MXPA02005456A (tr)
NO (1) NO323135B1 (tr)
PE (1) PE20011010A1 (tr)
PL (1) PL356772A1 (tr)
PT (1) PT1244642E (tr)
TR (2) TR200401772T4 (tr)
TW (1) TW555753B (tr)
WO (1) WO2001040207A1 (tr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317885B1 (it) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia.
US6787552B2 (en) * 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
GB0214139D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
DE602004010889T2 (de) * 2003-02-14 2008-12-11 Eli Lilly And Co., Indianapolis Sulfonamid-derivate als ppar-modulatoren
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
DE10331496A1 (de) * 2003-07-01 2005-01-27 Bayer Cropscience Ag Verfahren zum Herstellen von Difluoracetessigsäurealkylestern
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
WO2005095364A1 (ja) * 2004-03-30 2005-10-13 Daiichi Pharmaceutical Co. Ltd. フェノキシ酢酸誘導体及びそれを用いた医薬
JP2007230868A (ja) * 2004-03-30 2007-09-13 Dai Ichi Seiyaku Co Ltd 二環性化合物及びそれを用いた医薬
DE102004016845A1 (de) * 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
US20070202179A1 (en) * 2004-04-09 2007-08-30 FAULKNER Patrick Low Dose Pharmaceutical Products
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
JP2008530154A (ja) * 2005-02-15 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒアクチベーターとしてのアミド誘導体
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
JP3795515B1 (ja) 2005-08-10 2006-07-12 善典 中川 半導体光電気化学セルの製造方法
RU2435764C2 (ru) 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
RU2480453C2 (ru) 2007-03-08 2013-04-27 Альбирео Аб Новые соединения
UA105758C2 (uk) * 2007-07-19 2014-06-25 Х. Луннбек А/С 5-членні гетероциклічні аміди та споріднені сполуки
KR100882261B1 (ko) 2007-07-25 2009-02-06 삼성전기주식회사 인쇄회로기판의 제조 방법 및 장치
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
NZ588612A (en) 2008-04-15 2012-08-31 Nippon Chemiphar Co Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR)
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010071813A1 (en) * 2008-12-19 2010-06-24 Aryx Therapeutics, Inc. AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
HUP0003881A3 (en) * 1997-10-02 2001-04-28 Sankyo Co Amidocarboxylic acid derivatives
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제

Also Published As

Publication number Publication date
ATE265442T1 (de) 2004-05-15
AU758758B2 (en) 2003-03-27
NO20022467D0 (no) 2002-05-24
EP1244642A1 (en) 2002-10-02
PE20011010A1 (es) 2001-10-18
TW555753B (en) 2003-10-01
KR20020058073A (ko) 2002-07-12
AU2003001A (en) 2001-06-12
BR0016067A (pt) 2002-08-06
CO5251452A1 (es) 2003-02-28
DE60010333T2 (de) 2005-06-16
HUP0203532A2 (hu) 2003-02-28
AR035631A1 (es) 2004-06-23
CZ20021903A3 (cs) 2003-01-15
CN1184215C (zh) 2005-01-12
US6518290B1 (en) 2003-02-11
HK1047435A1 (en) 2003-02-21
DK1244642T3 (da) 2004-08-16
GC0000215A (en) 2006-03-29
PL356772A1 (en) 2004-07-12
PT1244642E (pt) 2004-09-30
IL149582A0 (en) 2002-11-10
NO20022467L (no) 2002-07-26
EP1244642B1 (en) 2004-04-28
KR100706735B1 (ko) 2007-04-13
NO323135B1 (no) 2007-01-08
HUP0203532A3 (en) 2005-01-28
MXPA02005456A (es) 2002-11-29
DE60010333D1 (de) 2004-06-03
CN1402716A (zh) 2003-03-12
IL149582A (en) 2008-11-26
ES2219423T3 (es) 2004-12-01
WO2001040207A1 (en) 2001-06-07
JP2003515597A (ja) 2003-05-07
JP3884290B2 (ja) 2007-02-21
TR200201473T2 (tr) 2002-09-23
CA2393190A1 (en) 2001-06-07
HK1047435B (zh) 2004-11-26

Similar Documents

Publication Publication Date Title
TR200401772T4 (tr) hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri.
CA2378183A1 (en) Antibacterial heterobicyclic substituted phenyl oxazolidinones
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
NO995846L (no) Oksazolidinon-antibakterielle midler med en tiokarbonylfunksjonalitet
MXPA03010584A (es) Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas.
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
TR200103612T2 (tr) Tiazol ve oksazol türevleri ve farmasötik kullanımları
NO20062629L (no) Oksazolderivater av tetrackliner
PE20011089A1 (es) Tioamidas de oxazolidinona con sustituyentes de piperazin-amida
TR200000736T2 (tr) İkame edilmiş kroman türevleri.
ATE258930T1 (de) Dihydrobenzifurane
WO2003011859A3 (en) Oxazolidinone derivatives as antibacterial agents
MY132656A (en) Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
DE60013188D1 (de) Fungiizide 6-(trifluormethyl-phenyl)-triazolpyrimidine
TR200001750T2 (tr) Nöro-koruyucu maddeler olarak yararlı yeni bileşikler.
DE69228877T2 (de) Benzoxazol, benzothiazol und benzimidazol derivate als fungizide
GB0116966D0 (en) Anittumoral compounds
NO20001228D0 (no) Fremgangsmate for fremstilling av N-(5-(difenylfosfinoylmetyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl)-N-metylmetansulfonamid
FI942265A0 (fi) 2-aminopyratsin-5-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
BR0014303A (pt) Sultam e sultona derivados de oxazolidinonas